About novavax inc. - NVAX
NVAX At a Glance
| Phone | 1-240-268-2000 | Revenue | 1.12B | |
| Industry | Biotechnology | Net Income | 440.30M | |
| Sector | Health Technology | 2025 Sales Growth | 64.694% | |
| Fiscal Year-end | 12 / 2026 | Employees | 749 | |
| View SEC Filings |
NVAX Valuation
| P/E Current | 3.672 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 2.642 |
| Price to Sales Ratio | 1.035 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 1.177 |
| Enterprise Value to Sales | 0.619 |
| Total Debt to Enterprise Value | 0.40 |
NVAX Efficiency
| Revenue/Employee | 1,499,971.963 |
| Income Per Employee | 587,853.138 |
| Receivables Turnover | 10.554 |
| Total Asset Turnover | 0.807 |
NVAX Liquidity
| Current Ratio | 2.127 |
| Quick Ratio | 2.102 |
| Cash Ratio | 1.622 |
NVAX Profitability
| Gross Margin | 93.668 |
| Operating Margin | 50.136 |
| Pretax Margin | 39.357 |
| Net Margin | 39.191 |
| Return on Assets | 31.614 |
| Return on Equity | N/A |
| Return on Total Capital | 292.959 |
| Return on Invested Capital | N/A |
NVAX Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 185.001 |
| Total Debt to Total Assets | 23.508 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 176.761 |
Novavax Inc. in the News
Vaccine makers see stock price boost on Biden admin COVID shot push
News that the Biden administration is planning to push for Americans to get the updated COVID vaccines this fall caused several vaccine manufacturers' stock prices to rise Monday.
Novavax's COVID vaccine recommended by CDC for children aged 12 through 17
Novavax's protein-based Coronavirus vaccine has been recommended by the US CDC for adolescents aged 12-17 years old after receiving emergency use authorization for adults in June.
Novavax expects Omicron-targeting vaccine by fourth quarter
Biotech company Novavax said it expects to be able to provide an Omicron-targeting vaccine in the fourth quarter of this year. Its vaccine is under FDA review.
Novavax COVID-19 vaccine recommended for approval by FDA advisory committee
A panel of vaccine experts recommended Novavax's COVID-19 vaccine for emergency use authorization on Tuesday, potentially paving the way for a fourth vaccine option.
Merck COVID-19 pill success slams Moderna shares, shakes up health care sector
Positive clinical trial results for Merck & Co's experimental antiviral COVID-19 pill reverberated through the health care sector on Friday, sending the drugmaker's stock price soaring while denting high-flying shares of vaccine companies and makers of other coronavirus therapies.
Novavax sets back COVID-19 vaccine FDA authorization request to fourth quarter
Maryland-based biotech Novavax announced a delay in plans to file for U.S. FDA authorization of its COVID-19 vaccine.
Novavax CEO: COVID-19 booster to be 'biggest market' in US
Novavax’s CEO said he believes boosters will be the company’s “biggest market” in the U.S. once it receives regulatory approval for its COVID-19 vaccine.